Displaying results 1 - 12 of 16
Metabolism, Alcohol & Toxicity
Non-alcoholic fatty liver disease: A patient guideline • This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and comes with a high disease burden. Yet, there is a lot of unawareness. Furthermore, many aspects of the disease are still to be unravelled, which has an important impact on the information that is given (or not) to patients. Its management requires a close interaction between patients and their many healthcare providers. It is important for patients to develop a full understanding of NAFLD in order to enable them to take an active role in their disease management. This guide summarises the current knowledge relevant to NAFLD and its management. It has been developed by patients, patient representatives, clinicians and scientists and is based on current scientific recommendations, intended to support patients in making informed decisions. Click here to download the short version and here to download the publication in PDF format. EASL NAFLD-NASH Patient Guideline Short Version Non-alcoholic fatty liver disease: A patient guideline
EASL Studio S3 E6: How to improve end-of-life care in liver disease? • Description In honour of World Hospice and Palliative Care Day (8 October), this EASL Studio episode examines: When is the best time to think about end-of-life care in liver disease? What does it mean for the liver care team? When and how should patients be referred to specialised palliative care? Faculty Dr Patrizia Künzler-Heule (Moderator) Prof. Philip Larkin (Faculty) Dr Philip Berry (Faculty) ℹ️ Please click here to access the podcast version of this EASL Studio episode.
EASL Studio S1 E1: Liver Cancer Awareness Month • Description Since 2020 EASL Studio has been a part of the International Liver Congress (ILC), bringing you the most up-to-date research live from the congress. But EASL Studio is evolving. EASL Studio is now a new platform through which we will be exploring hepatology every week, from every angle. Through live debates, interviews, and roundtable discussions, EASL Studio will be a chance to peak behind the scenes. Hear the expert’s opinion on the latest research. Discover what it’s like to be a young investigator. Meet the Nurses, the allied health professionals, and the patients they work with. Watch on-demand the first Session that was broadcasted on Wednesday 27 October 2021. Programme Time Title 00:00-04:12 Welcome and Introductions Thomas Berg, University Clinic Leipzig, Germany Maria Buti, Valle Hebron University, Spain 04:12-28:26 Topic 1: Raising awareness about Liver Cancer Nathalie Ganne-Carrié, Avicenne Hospital, France Peter Jepsen, University of Aarhus, Denmark 28:26-47:34 Topic 2: Liver Cancer Summit: Highlights from 2021 and what awaits us in 2022 Angela Lamarca, University of Manchester, United Kingdom Jean-Charles Nault, Avicenne Hospital, France 47:34-50:31 Closing remarks Thomas Berg, University Clinic Leipzig, Germany Maria Buti, Valle Hebron University, Spain
EASL Studio Special Edition: Highlights of Liver Cancer Summit 2022 • Description The highlights of EASL's Liver Cancer Summit 2022 - What is practice changing right now and where are the current controversies? How do our experts interprete the new data on Immunotherapy in HCC and CCA, and what to expect in 2022: Upcoming trials, New combinations, New biomarkers Watch on-demand the session that was broadcast Friday 4 February 2022.
EASL Studio Special Edition: Live from Viral Hepatitis Elimination Conference 2022 • Description The WHO goal of eliminating viral hepatitis by 2030 has led to a surge in activities to achieve a world free from viral liver disease. What steps must be taken? How do you define sustainable elimination? Listen to the experts debriefing the Viral Hepatitis Elimination Conference 2022. Discover the highlights of the conference and learn more about what successful countries have done to achieve viral hepatitis elimination.
EASL Policy Dialogues Episode 1: Drug use, viral hepatitis, and Europe • Description In this first episode, the experts are discussing the multifaceted issue of drug use in relation to the hepatitis C elimination in Europe. How far are we from hepatitis C elimination in Europe? How are drug use and hepatitis C issues related? How can the work of the European Parliament contribute to eliminating hepatitis?
Metabolism, Alcohol & Toxicity
EASL Policy Dialogues Episode 2: The liver, alcohol, and politics • Description In this second episode, the experts discuss the impact of alcohol consumption on the liver and the stakes around alcohol policy. What are the key trends in Europe around alcohol consumption and alcohol-related liver disease? How can the work of the European Parliament make society a safer place, with less alcohol use? What’s the impact of the alcohol industry on politics?
EASL Policy Dialogues Episode 3: Liver cancer: The risk of ignorance • Description In this third episode, the experts discuss the worrying burden of liver cancer in Europe and the political actions needed to invert the curve. How can deaths from liver cancer be prevented and how is EASL and the hepatology community working towards this goal? What is the European Union doing for cancer control, and which are the challenges?
EASL Studio S3 E5: JHEP Live: Stigma and alcohol • Description People suffering from alcohol-related liver (ALD) disorders are subject to several forms of stigma. If not addressed, stigma may lead towards unfavourable health outcomes. This JHEP Live – based on a recent review – discusses: What forms of stigma do people suffering from ALD face? How does stigma affect them? What can be done about it? ℹ️ Read this article for more information: G. Schomerus et al. The stigma of alcohol-related liver disease and its impact on healthcare Journal of Hepatology 2022 vol. 77 : 516–524 Faculty Prof. Patrizia Burra (Moderator) Prof. Georg Schomerus (Moderator) Dr Patrizia Carrieri (Faculty) Prof. Philippe Mathurin (Faculty) ℹ️ Please click here to access the podcast version of this EASL Studio episode.
EASL Studio Podcast S3 E5: JHEP Live: Stigma and alcohol • Description People suffering from alcohol-related liver (ALD) disorders are subject to several forms of stigma. If not addressed, stigma may lead towards unfavourable health outcomes. This JHEP Live – based on a recent review – discusses: What forms of stigma do people suffering from ALD face? How does stigma affect them? What can be done about it? ℹ️ Read this article for more information: G. Schomerus et al. The stigma of alcohol-related liver disease and its impact on healthcare Journal of Hepatology 2022 vol. 77 : 516–524 Faculty Prof. Patrizia Burra (Moderator) Prof. Georg Schomerus (Moderator) Dr Patrizia Carrieri (Faculty) Prof. Philippe Mathurin (Faculty) Listen to the podcast